312 related articles for article (PubMed ID: 27409341)
1. Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels.
Beyrath J; Chekkat N; Smulski CR; Lombardo CM; Lechner MC; Seguin C; Decossas M; Spanedda MV; Frisch B; Guichard G; Fournel S
Oncotarget; 2016 Oct; 7(40):64942-64956. PubMed ID: 27409341
[TBL] [Abstract][Full Text] [Related]
2. Death receptor 5 is activated by fucosylation in colon cancer cells.
Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
[TBL] [Abstract][Full Text] [Related]
3. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
4. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.
Lemke J; Noack A; Adam D; Tchikov V; Bertsch U; Röder C; Schütze S; Wajant H; Kalthoff H; Trauzold A
J Mol Med (Berl); 2010 Jul; 88(7):729-40. PubMed ID: 20354842
[TBL] [Abstract][Full Text] [Related]
5. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.
Cretney E; Takeda K; Smyth MJ
Int J Biochem Cell Biol; 2007; 39(2):280-6. PubMed ID: 17097329
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a novel anti-DR5 monoclonal antibody WD1 with the potential to induce tumor cell apoptosis.
Wang J; Lin Z; Qiao CX; Lv M; Yu M; Xiao H; Wang Q; Wang L; Feng J; Shen B; Ma Y; Li Y
Cell Mol Immunol; 2008 Feb; 5(1):55-60. PubMed ID: 18318995
[TBL] [Abstract][Full Text] [Related]
7. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
[TBL] [Abstract][Full Text] [Related]
8. An HPLC method associated with a thermodynamic analysis to compare the binding of TRAIL and its nanovectorized form to death receptors DR4 and DR5 and their relationship to cytotoxicity.
Guillaume YC; Lethier L; André C
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Nov; 1036-1037():142-148. PubMed ID: 27750195
[TBL] [Abstract][Full Text] [Related]
9. Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.
Gasparian ME; Bychkov ML; Yagolovich AV; Dolgikh DA; Kirpichnikov MP
Biochemistry (Mosc); 2015 Aug; 80(8):1080-91. PubMed ID: 26547077
[TBL] [Abstract][Full Text] [Related]
10. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
Milutinovic S; Kashyap AK; Yanagi T; Wimer C; Zhou S; O'Neil R; Kurtzman AL; Faynboym A; Xu L; Hannum CH; Diaz PW; Matsuzawa S; Horowitz M; Horowitz L; Bhatt RR; Reed JC
Mol Cancer Ther; 2016 Jan; 15(1):114-24. PubMed ID: 26516157
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation.
Qiao C; Hu M; Guo L; Lv M; Lin Z; Geng J; Lang X; Li X; Li Y; Ma Y; Feng J; Shen B
BMC Immunol; 2012 Jul; 13():40. PubMed ID: 22788777
[TBL] [Abstract][Full Text] [Related]
12. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.
Tur V; van der Sloot AM; Reis CR; Szegezdi E; Cool RH; Samali A; Serrano L; Quax WJ
J Biol Chem; 2008 Jul; 283(29):20560-8. PubMed ID: 18474604
[TBL] [Abstract][Full Text] [Related]
13. Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.
Bychkov ML; Gasparian ME; Dolgikh DA; Kirpichnikov MP
PLoS One; 2014; 9(10):e109756. PubMed ID: 25310712
[TBL] [Abstract][Full Text] [Related]
14. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity.
Pavet V; Beyrath J; Pardin C; Morizot A; Lechner MC; Briand JP; Wendland M; Maison W; Fournel S; Micheau O; Guichard G; Gronemeyer H
Cancer Res; 2010 Feb; 70(3):1101-10. PubMed ID: 20103630
[TBL] [Abstract][Full Text] [Related]
15. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
Zhang Y; Zhang B
Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
[TBL] [Abstract][Full Text] [Related]
16. The characteristic of an anti-human DR5 antibody A6.
Wang YG; Zhao KP; Chen JG; Zhang JY; Yu M; Li Y; Shen BF
Cell Mol Immunol; 2008 Jun; 5(3):183-8. PubMed ID: 18582399
[TBL] [Abstract][Full Text] [Related]
17. The tetravalent anti-DR5 antibody without cross-linking direct induces apoptosis of cancer cells.
Liu F; Si Y; Liu G; Li S; Zhang J; Ma Y
Biomed Pharmacother; 2015 Mar; 70():41-5. PubMed ID: 25776477
[TBL] [Abstract][Full Text] [Related]
18. Developing TRAIL/TRAIL death receptor-based cancer therapies.
Yuan X; Gajan A; Chu Q; Xiong H; Wu K; Wu GS
Cancer Metastasis Rev; 2018 Dec; 37(4):733-748. PubMed ID: 29541897
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Importin β1 Augments the Anticancer Effect of Agonistic Anti-Death Receptor 5 Antibody in TRAIL-resistant Tumor Cells.
Kojima Y; Nishina T; Nakano H; Okumura K; Takeda K
Mol Cancer Ther; 2020 May; 19(5):1123-1133. PubMed ID: 32156787
[TBL] [Abstract][Full Text] [Related]
20. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]